The safety profiles were similar in both the treatment groups with mild-moderate adverse effects.

The PK characteristics and immunogenicity exhibited by HL02 were similar to that of the reference product, US-trastuzumab. The safety profiles were similar in both the treatment groups with mild-moderate adverse effects.While sarcoma immunology has…[Leer más]